| ESPEROVAX, INC. |
ESPEROVAX, INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
July 27, 2020 |
February 28, 2022 |
$0 |
| DEVELOP A SAFE AND EFFECTIVE THERAPEUTIC TO MITIGATE SEVERE OUTCOMES, INCLUDING BUT NOT LIMITED TO MORTALITY, IN PATIENTS WITH SEVERE INFECTION OR SEPSIS OF ANY ETIOLOGY. |
BIOAEGIS THERAPEUTICS INC |
Office of Assistant Secretary for Preparedness and Response - HHS |
June 11, 2021 |
March 31, 2022 |
$749,000 |
| LUMINEX XMAP SARS-COV-2 MULTI-ANTIGEN ANTIBODY TYPING ASSAY |
LUMINEX CORPORATION |
Office of Assistant Secretary for Preparedness and Response - HHS |
September 23, 2020 |
July 30, 2021 |
$0 |
| NCE POP END DATE FROM 30 APRIL 2021 TO 30 SEPTEMBER 2021
- EVIDATION COVID-19 DETECTION & FORECASTING MODEL PILOT |
EVIDATION HEALTH, INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
April 20, 2020 |
September 30, 2021 |
$0 |
| PERAHEALTH COVID-19 RISK TRIAGE TOOL |
PERAHEALTH, INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
April 15, 2021 |
February 28, 2022 |
$686,462 |
| EMERGENT CIADM MANUFACTURING CAPACITY RESERVATION AND EXPANSION |
EMERGENT MANUFACTURING OPERATIONS BALTIMORE LLC |
Office of Assistant Secretary for Preparedness and Response - HHS |
May 24, 2020 |
December 31, 2021 |
$22,815,455 |
| EXPANDING PRODUCTION CAPACITY FOR THE PANTHER FUSION SARS-COV-2 ASSAY |
HOLOGIC, INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
April 29, 2020 |
April 28, 2021 |
$0 |
| ASPR-21-00560 - BASE PERIOD FUNDS FOR LUMINEX CORPORATION - EXPAND THE USE OF THE ARIES SARS-COV-2 ASSAY |
LUMINEX CORPORATION |
Office of Assistant Secretary for Preparedness and Response - HHS |
February 18, 2021 |
February 17, 2022 |
$11,336,921 |
| COLORADO STATE VACCINE DEVELOPMENT FOR COVID-19 USING SOLAVAX |
COLORADO STATE UNIVERSITY |
Office of Assistant Secretary for Preparedness and Response - HHS |
March 31, 2021 |
July 30, 2021 |
$0 |
| IMMUNEXPRESS ASSESSMENT & TRIAGE OF PATIENTS WITH ESCALATING SIGNS OF COVID-19 DISEASE USING A HOST RESPONSE TEST FOR SEPSIS |
IMMUNEXPRESS INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
June 11, 2020 |
December 31, 2021 |
$0 |
| 98POINT6 TEXT-BASED MEDICAL CARE VIA A SMARTPHONE INTERFACE AND ARTIFICIAL INTELLIGENCE TO ASSESS, TRIAGE, DIAGNOSE AND TREAT COVID-19 |
98POINT6 INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
September 11, 2020 |
April 30, 2021 |
$0 |
| DEVELOPMENT OF SIMPLEXA COVID-19 DIRECT ASSAY |
DIASORIN MOLECULAR LLC |
Office of Assistant Secretary for Preparedness and Response - HHS |
March 11, 2020 |
February 03, 2021 |
$0 |
| DIASORIN LIAISON SARS-COV-2 S1/S2 IGG |
DIASORIN INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
April 10, 2020 |
February 03, 2021 |
$0 |
| ASPR-21-00574 -- BASE PERIOD FUND TO MBIO DIAGNOSTICS TO DEVELOP THEIR LIGHTDECK SARS-COV ULTRA-RAPID ANTIGEN TEST TO ACHIEVE EUA AND 510K CLEARANCE |
MBIO DIAGNOSTICS, INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
February 03, 2021 |
February 02, 2022 |
$5,654,478 |
| UPDATE CONTRACTOR'S KEYS PERSONNEL |
EMERGENT MANUFACTURING OPERATIONS BALTIMORE LLC |
Office of Assistant Secretary for Preparedness and Response - HHS |
May 24, 2020 |
December 31, 2021 |
$0 |
| ASPR-21-00523 -- BASE PERIOD FUNDS TO HOLOGIC INC RESPIRATORY PANEL (SARS-COV FLUA FLUB RSV) FOR USE ON THE HOLOGIC PANTHER FUSION SYSTEM |
HOLOGIC, INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
January 15, 2021 |
January 13, 2022 |
$11,414,617 |
| THE PURPOSE OF THIS MODIFICATION IS TO EXERCISE THE OPTIONAL CLIN 0002. |
CORAM LLC |
Office of Assistant Secretary for Preparedness and Response - HHS |
November 25, 2020 |
February 24, 2021 |
$494,000 |
| DIASORIN MOLECULAR LLC FOR COVID-19 LABORATORY DIAGNOSTICS - PCR SIMPLEXA DIRECT ASSAYS WITH 510(K) CLEARANCE |
DIASORIN MOLECULAR LLC |
Office of Assistant Secretary for Preparedness and Response - HHS |
January 05, 2021 |
January 04, 2022 |
$4,040,000 |
| PILOT STUDY WITH CVS TO INFUSE THIS THERAPY AND MONITOR PATIENTS WITHIN THEIR OWN HOMES, WITH SKILLED NURSING PROFESSIONALS. |
CORAM LLC |
Office of Assistant Secretary for Preparedness and Response - HHS |
November 25, 2020 |
February 24, 2021 |
$0 |
| IGF AN NHP EFFICACY STUDY OF BIO 300 FOR MITIGATOR FOR DEARE-INDUCED PNEUMONITIS AND PULMONARY FIBROSIS |
HUMANETICS CORPORATION |
National Institutes of Health |
March 29, 2018 |
June 30, 2022 |
$0 |
| EMPATICA EMPACT: EARLY MONITORING PLATFORM AGAINST COVID-19 TRANSMISSION |
EMPATICA, INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
June 18, 2020 |
April 30, 2021 |
$0 |
| ESTABLISHMENT OF HIGH THROUGHPUT SARS-COV-2 BINDING ANTIBODY IMMUNOASSAY CAPABILITY AND TESTING OF HUMAN SERUM SAMPLES |
NEXELIS LABORATORIES CANADA INC |
Office of Assistant Secretary for Preparedness and Response - HHS |
December 08, 2020 |
December 13, 2021 |
$712,859 |
| EXTEND THE CONTRACT PURCHASE ORDER PERIOD OF PERFORMANCE AT NO ADDITIONAL COST TO THE GOVERNMENT AND TO CHANGE THE CONTRACTING OFFICER. |
CHEMBIO DIAGNOSTIC SYSTEMS INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
July 05, 2020 |
January 29, 2021 |
$0 |
| DIASORIN SARS-COV-2 TRIMERICS IGG ASSAY & 501(K) VALIDATION |
DIASORIN INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
November 10, 2020 |
November 09, 2021 |
$0 |
| DEVELOPMENT OF DUAL PATH PLATFORM (DPP) COVID-19 ANTIGEN SYSTEM, AS WELL AS ACHIEVEMENT OF EMERGENCY USE AUTHORIZATION (EUA) FROM THE U.S. FOOD AND DRUG ADMINISTRATION (FDA). |
CHEMBIO DIAGNOSTIC SYSTEMS INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
December 02, 2020 |
November 30, 2021 |
$12,691,726 |
| PILOT STUDY WITH CVS TO INFUSE THIS THERAPY AND MONITOR PATIENTS WITHIN THEIR OWN HOMES, WITH SKILLED NURSING PROFESSIONALS. |
CORAM LLC |
Office of Assistant Secretary for Preparedness and Response - HHS |
November 25, 2020 |
February 24, 2021 |
$494,000 |
| ESTABLISHMENT OF HIGH THROUGHPUT SARS-COV-2 BINDING ANTIBODY IMMUNOASSAY CAPABILITY AND TESTING OF HUMAN SERUM SAMPLES |
PPD DEVELOPMENT, L.P. |
Office of Assistant Secretary for Preparedness and Response - HHS |
November 16, 2020 |
November 22, 2021 |
$2,750,095 |
| DIASORIN SARS-COV-2 TRIMERICS IGG ASSAY&501(K) VALIDATION |
DIASORIN INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
November 10, 2020 |
November 09, 2021 |
$820,000 |
| ACCULA FLU/SARS-COV-2 INTEGRATED TEST DEVELOPMENT |
MESA BIOTECH, INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
November 05, 2020 |
November 04, 2021 |
$12,991,595 |
| SIEMENS HEALTHINEERS DEVELOPMENT OF SARS-COV-2 ANTIGEN TEST (COV2AG) FOR THE ADVIA CENTAUR AND ATELLICA IM SYSTEMS |
SIEMENS HEALTHCARE DIAGNOSTICS INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
November 02, 2020 |
November 01, 2021 |
$13,000,000 |
| APTIMA SARS-COV-2 TESTS ON HOLOGIC PANTHER SYSTEMS |
HOLOGIC, INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
August 04, 2020 |
August 03, 2021 |
$2,429,380 |
| DIASORIN LIAISON SARS-COV-2 S1/S2 IGG |
DIASORIN INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
April 10, 2020 |
February 03, 2021 |
-$55,045 |
| CHANGE IN OTAO AND OTAS OF ADVANCED AGREEMENT FOR THE COVID19 VACCINE DEVELOPMENT AND MANUFACTURING |
ASTRAZENECA PHARMACEUTICALS LP |
Office of Assistant Secretary for Preparedness and Response - HHS |
May 20, 2020 |
October 31, 2020 |
$0 |
| CHANGE IN OTAO AND OTAS OF ADVANCED AGREEMENT FOR THE COVID19 VACCINE DEVELOPMENT AND MANUFACTURING |
ASTRAZENECA PHARMACEUTICALS LP |
Office of Assistant Secretary for Preparedness and Response - HHS |
May 20, 2020 |
October 31, 2020 |
$0 |
| FFP PURCHASE ORDER FOR SITE REIMBURSEMENT, ORTHO TESTING, NAB TESTING, AND TREATMENT/CONTROL STUDY AT THE MAYO CLINIC CCP EAP |
MAYO CLINIC |
Office of Assistant Secretary for Preparedness and Response - HHS |
July 01, 2020 |
June 30, 2021 |
$17,509,398 |
| PROVIDE FOR CONSIDERATION / OFFSET IN COST FOR DOD PERSONNEL AGREEMENT |
EMERGENT MANUFACTURING OPERATIONS BALTIMORE LLC |
Office of Assistant Secretary for Preparedness and Response - HHS |
May 24, 2020 |
December 31, 2021 |
$0 |
| CHANGE IN OTAO AND OTAS OF ADVANCED AGREEMENT FOR THE COVID19 VACCINE DEVELOPMENT AND MANUFACTURING |
ASTRAZENECA PHARMACEUTICALS LP |
Office of Assistant Secretary for Preparedness and Response - HHS |
May 20, 2020 |
October 31, 2020 |
$0 |
| THIRD NO-COST EXTENSION FOR EXPIRATION OF ADVANCED AGREEMENT FOR THE COVID19 VACCINE DEVELOPMENT AND MANUFACTURING |
ASTRAZENECA PHARMACEUTICALS LP |
Office of Assistant Secretary for Preparedness and Response - HHS |
May 20, 2020 |
October 31, 2020 |
$0 |
| BECKMAN COULTER - MONOCYTE DISTRIBUTION WIDTH (MDW) FOR RAPID DETECTION OF MIS-C ASSOCIATED WITH COVID-19 IN PEDIATRIC PATIENTS |
BECKMAN COULTER, INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
September 28, 2020 |
December 31, 2021 |
$694,000 |
| DEVELOPMENT OF A MOLECULAR DIAGNOSTIC TEST TO DETECT SARS-COV-2 USING THE HOLOGIC PANTHER FUSION? SYSTEM |
HOLOGIC, INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
July 06, 2020 |
September 24, 2020 |
$0 |
| INTEGRATE SARS-COV-2 WITH NXTAG? RESPIRATORY PATHOGEN PANEL AND SUBMIT 510(K) |
LUMINEX CORPORATION |
Office of Assistant Secretary for Preparedness and Response - HHS |
September 24, 2020 |
September 23, 2021 |
$5,389,813 |
| LUMINEX XMAP SARS-COV-2 MULTI-ANTIGEN ANTIBODY TYPING ASSAY |
LUMINEX CORPORATION |
Office of Assistant Secretary for Preparedness and Response - HHS |
September 23, 2020 |
July 30, 2021 |
$683,500 |
| TANGEN SARS-COV-2 ASSAY - NCE TO ALLOW TIME FOR THE EUA TO MOVE THROUGH FDA APPROVAL. |
TANGEN BIOSCIENCES, INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
April 15, 2020 |
October 31, 2020 |
$0 |
| UPDATE FAR CLAUSES IN TASK ORDER |
EMERGENT MANUFACTURING OPERATIONS BALTIMORE LLC |
Office of Assistant Secretary for Preparedness and Response - HHS |
May 24, 2020 |
December 31, 2021 |
$0 |
| ADVIA CENTAUR SARS-COV-2 TOTAL , ATELLICA IM SARS-COV-2 TOTAL (COV2T) |
SIEMENS HEALTHCARE DIAGNOSTICS INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
September 17, 2020 |
September 16, 2021 |
$13,000,000 |
| EXTEND FOR EXPIRATION OF ADVANCED AGREEMENT FOR THE COVID19 VACCINE DEVELOPMENT AND MANUFACTURING |
ASTRAZENECA PHARMACEUTICALS LP |
Office of Assistant Secretary for Preparedness and Response - HHS |
May 20, 2020 |
October 31, 2020 |
$0 |
| 98POINT6 TEXT-BASED MEDICAL CARE VIA A SMARTPHONE INTERFACE AND ARTIFICIAL INTELLIGENCE TO ASSESS, TRIAGE, DIAGNOSE AND TREAT COVID-19 |
98POINT6 INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
September 11, 2020 |
April 30, 2021 |
$700,000 |
| CRO ASSISTANCE FOR THE ACTIV-1 MASTER PROTOCOL |
TECHNICAL RESOURCES INC |
Office of Assistant Secretary for Preparedness and Response - HHS |
August 17, 2020 |
August 16, 2021 |
$69,824,321 |
| TO DEVELOP RAPID AND ACCURATE POINT OF CARE AND OVER THE COUNTER TESTS FOR DETECTION OF SARS-COV-2 ANTIBODIES IN BLOOD AND ACHIEVE EMERGENCY USE AUTHORIZATION (EUA). |
NOWDIAGNOSTICS, INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
August 28, 2020 |
April 27, 2021 |
$695,500 |
| ORTHO CLINICAL DEVELOPMENT OF VITROS MICROWELL ASSAYS FOR TOTAL AND IGG ANTIBODIES TO SARS-COV-2 |
ORTHO-CLINICAL DIAGNOSTICS, INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
June 12, 2020 |
September 30, 2020 |
$0 |
| ISSUE EXTENSION OF TARGET DATE OF DEFINITIZATION OF ADVANCED AGREEMENT FOR OTHER TRANSACTION AGREEMENT (OTA)FOR THE
COVID19 VACCINE DEVELOPMENT AND MANUFACTURING |
ASTRAZENECA PHARMACEUTICALS LP |
Office of Assistant Secretary for Preparedness and Response - HHS |
May 20, 2020 |
October 31, 2020 |
$0 |
| COVID-19 - MESA BIOTECH, INC. - RESEARCH&DEVELOPMENT OF QUALITATIVE, VISUALLY-READ PCR TEST. |
MESA TECH INTERNATIONAL, INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
March 13, 2020 |
August 07, 2020 |
$0 |
| COVID-19 - SIEMENS - R&D OF AN AUTOMATED IMMUNOASSAY |
SIEMENS HEALTHCARE DIAGNOSTICS INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
May 28, 2020 |
April 01, 2021 |
$0 |
| UPGRADE TASK ORDER TO A DEFENSE PRIORITIES ALLOCATIONS SYSTEM RATING TASK ORDER |
EMERGENT MANUFACTURING OPERATIONS BALTIMORE LLC |
Office of Assistant Secretary for Preparedness and Response - HHS |
May 24, 2020 |
December 31, 2021 |
$0 |
| VERNDARI, INC. |
VERNDARI, INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
July 24, 2020 |
June 30, 2021 |
$0 |
| UCONN - SINGLE-ADMINISTRATION MICRONEEDLE SKIN PATCH FOR NOVEL VACCINATION TECHNOLOGY |
UNIVERSITY OF CONNECTICUT |
Office of Assistant Secretary for Preparedness and Response - HHS |
August 18, 2020 |
August 31, 2021 |
$432,990 |
| TANGEN SARS-COV-2 ASSAY |
TANGEN BIOSCIENCES, INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
April 15, 2020 |
October 31, 2020 |
$0 |
| COVID-19 - VELA DIAGNOSTICS USA INC.- RESEARCH&DEVELOPMENT OF PROBE-BASED REVERSE TRANSCRIPTASE PCR TEST. |
VELA DIAGNOSTICS USA INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
March 27, 2020 |
October 31, 2020 |
$0 |
| LUMINEX DEVELOPMENT OF ARIES SARS-COV-2 ASSAY |
LUMINEX CORPORATION |
Office of Assistant Secretary for Preparedness and Response - HHS |
March 27, 2020 |
August 07, 2020 |
$0 |
| VAXESS - MIMIX-COVID PRE-FUSION SPIKE PROTEIN VACCINE PATCH MFG: SCALING TO 100M UNITS OF SHELF-STABLE, SELF-APPLIED, SINGLE-DOSE VACCINE |
VAXESS TECHNOLOGIES INC |
Office of Assistant Secretary for Preparedness and Response - HHS |
August 10, 2020 |
June 30, 2021 |
$749,000 |
| APTIMA SARS-COV-2 TESTS ON HOLOGIC PANTHER SYSTEMS |
HOLOGIC, INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
August 04, 2020 |
August 03, 2021 |
$8,912,000 |
| I. AMENDMENT PURPOSE: BY THE PARTIES? MUTUAL AGREEMENT AND WITHIN THE EXISTING AGREEMENT?S GENERAL SCOPE, THIS AMENDMENT NO. 0007 BILATERALLY ACCOMPLISHES THE FOLLOWING:
A. EXTEND THE PERIOD OF PERFORMANCE OF CLIN 0001A FROM 31 JULY 2020 TO 30 JUNE |
JANSSEN RESEARCH & DEVELOPMENT, LLC |
Office of Assistant Secretary for Preparedness and Response - HHS |
September 21, 2018 |
December 31, 2024 |
$0 |
| COVID-19 - RAPID ANTIGEN AND ANTIBODY TEST |
NANOMIX, INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
April 02, 2020 |
November 30, 2020 |
$0 |
| VERNDARI, INC. |
VERNDARI, INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
July 24, 2020 |
June 30, 2021 |
$698,215 |
| SUPPLEMENTAL WORK-SARS-COV-2 |
HUMANETICS CORPORATION |
National Institutes of Health |
March 29, 2018 |
June 30, 2022 |
$2,137,190 |
| GENMARK DX EPLEX RESPIRATORY PATHOGEN V2 PANEL |
GENMARK DIAGNOSTICS, INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
March 20, 2020 |
September 30, 2020 |
$0 |
| COVID-19 - CHEMBIO DIAGNOSTICS INC - R&D OF A SARS-COV-2 AG SYSTEM |
CHEMBIO DIAGNOSTIC SYSTEMS INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
July 05, 2020 |
January 29, 2021 |
$0 |
| COVID-19 -- INBIOS R&D OF AN ANTIBODY DIAGNOSTIC |
INBIOS INTERNATIONAL INC |
Office of Assistant Secretary for Preparedness and Response - HHS |
April 24, 2020 |
December 01, 2020 |
$155,055 |
| EVIDATION COVID-19 DETECTION&FORECASTING MODEL PILOT |
EVIDATION HEALTH, INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
April 20, 2020 |
September 30, 2021 |
$0 |
| DIASORIN LIAISON SARS-COV-2 S1/S2 IGG |
DIASORIN INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
April 10, 2020 |
February 03, 2021 |
$111,090 |
| COVID-19 - CHEMBIO DIAGNOSTICS INC - R&D OF A SARS-COV-2 AG SYSTEM |
CHEMBIO DIAGNOSTIC SYSTEMS INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
July 05, 2020 |
January 29, 2021 |
$628,071 |
| HEMEMICS HEMBOX: A RAPID, POINT-OF-CARE DIAGNOSTIC TOOL FOR NOVEL VIRUSES |
HEMEMICS BIOTECHNOLOGIES, INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
April 09, 2020 |
July 01, 2020 |
$0 |
| LUMINEX NXTAG COV EXTENDED PANEL DEVELOPMENT |
LUMINEX CORPORATION |
Office of Assistant Secretary for Preparedness and Response - HHS |
March 26, 2020 |
July 01, 2020 |
$0 |
| COLORADO STATE VACCINE DEVELOPMENT FOR COVID-19 USING SOLAVAX |
COLORADO STATE UNIVERSITY |
Office of Assistant Secretary for Preparedness and Response - HHS |
March 31, 2021 |
July 30, 2021 |
$699,994 |
| AN NHP EFFICACY STUDY OF BIO 300 FOR MITIGATOR FOR DEARE-INDUCED PNEUMONITIS AND PULMONARY FIBROSIS. SARS COV-2 |
HUMANETICS CORPORATION |
National Institutes of Health |
March 29, 2018 |
June 30, 2022 |
$503,859 |
| EMPATICA EMPACT: EARLY MONITORING PLATFORM AGAINST COVID-19 TRANSMISSION |
EMPATICA, INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
June 18, 2020 |
April 30, 2021 |
$717,807 |
| ADDED A SUPPLEMENT FOR KEVZARA. THIS COVERS THE OVER-RECRUITMENT OF 1,470 PARTICIPANTS. |
REGENERON PHARMACEUTICALS, INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
September 21, 2017 |
May 31, 2026 |
$53,517,946 |
| MBIO HIGH PERFORMANCE POINT-OF-CARE ANTIBODY TEST TO ASSESS IMMUNITY TO SARS-COV-2 VIRUS AND CONFIRM POSITIVE ANTIBODY TESTS |
MBIO DIAGNOSTICS, INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
June 17, 2020 |
March 31, 2021 |
$629,595 |
| ORTHO CLINICAL DEVELOPMENT OF VITROS MICROWELL ASSAYS FOR TOTAL AND IGG ANTIBODIES TO SARS-COV-2 |
ORTHO-CLINICAL DIAGNOSTICS, INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
June 12, 2020 |
September 30, 2020 |
$678,000 |
| IMMUNEXPRESS ASSESSMENT&TRIAGE OF PATIENTS WITH ESCALATING SIGNS OF COVID-19 DISEASE USING A HOST RESPONSE TEST FOR SEPSIS |
IMMUNEXPRESS INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
June 11, 2020 |
December 31, 2021 |
$599,549 |
| COVID-19 - R&D OF AN ANTIBODY TEST |
ORASURE TECHNOLOGIES, INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
June 04, 2020 |
April 01, 2021 |
$629,217 |
| HEMEMICS HEMBOX: A RAPID, POINT-OF-CARE DIAGNOSTIC TOOL FOR NOVEL VIRUSES |
HEMEMICS BIOTECHNOLOGIES, INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
April 09, 2020 |
July 01, 2020 |
-$613,000 |
| COVID-19 - SNAPDRAGON CHEMISTRY - R&D OF A CONTINUOUS MANUFACTURING PLATFORM |
SNAPDRAGON CHEMISTRY, INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
May 29, 2020 |
May 01, 2021 |
$691,878 |
| COVID-19 - QUIDEL - ANTIGEN ASSAY |
QUIDEL CORPORATION |
Office of Assistant Secretary for Preparedness and Response - HHS |
May 29, 2020 |
April 08, 2021 |
$634,644 |
| COVID-19 - SIEMENS - R&D OF AN AUTOMATED IMMUNOASSAY |
SIEMENS HEALTHCARE DIAGNOSTICS INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
May 28, 2020 |
April 01, 2021 |
$602,275 |
| COVID-19 - VITAL CONNECT, INC. - R&D FOR SYSTEM AND ALGORITHM OPTIMIZATION FOR PATIENT POPULATION
REPORTS&OTHER DELIVERABLES |
VITAL CONNECT, INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
May 20, 2020 |
January 15, 2021 |
$0 |
| EMERGENT CIADM MANUFACTURING CAPACITY RESERVATION AND EXPANSION |
EMERGENT MANUFACTURING OPERATIONS BALTIMORE LLC |
Office of Assistant Secretary for Preparedness and Response - HHS |
May 24, 2020 |
December 31, 2021 |
$628,250,000 |
| ISSUE ADVANCED AGREEMENT PRIOR TO AWARD OF AN OTHER TRANSACTION AGREEMENT (OTA)FOR THE
COVID19 VACCINE DEVELOPMENT AND MANUFACTURING |
ASTRAZENECA PHARMACEUTICALS LP |
Office of Assistant Secretary for Preparedness and Response - HHS |
May 20, 2020 |
October 31, 2020 |
$413,200,000 |
| COVID-19 - VITAL CONNECT, INC. - R&D FOR SYSTEM AND ALGORITHM OPTIMIZATION FOR PATIENT POPULATION
REPORTS&OTHER DELIVERABLES |
VITAL CONNECT, INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
May 20, 2020 |
January 15, 2021 |
$592,791 |
| A MULTI-SITE, RANDOMIZED, DOUBLE-BLIND, MULTI-ARM HISTORICAL CONTROL, COMPARATIVE TRIAL OF THE SAFETY AND EFFICACY OF HYDROXYCHLOROQUINE AND THE COMBINATION OF HYDROXYCHLOROQUINE AND FAMOTIDINE FOR THE TREATMENT OF MODERATE TO SEVERE COVID-19 DISEASE |
ALCHEM LABORATORIES CORP |
Office of Assistant Secretary for Preparedness and Response - HHS |
April 14, 2020 |
September 30, 2020 |
$0 |
| PROJECT RTOR BIO-AMT-1021: DEVELOPMENT OF ANIMAL MODELS FOR EVALUATION OF MEDICAL
COUNTERMEASURES FOR SARS-COV-2 |
LOVELACE BIOMEDICAL & ENVIRONMENTAL RESEARCH INSTITUTE INC |
Office of Assistant Secretary for Preparedness and Response - HHS |
March 30, 2020 |
June 30, 2021 |
$2,177,532 |
| EXPANDING PRODUCTION CAPACITY FOR THE PANTHER FUSION SARS-COV-2 ASSAY |
HOLOGIC, INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
April 29, 2020 |
April 28, 2021 |
$13,000,000 |
| COVID-19 -- INBIOS R&D OF AN ANTIBODY DIAGNOSTIC |
INBIOS INTERNATIONAL INC |
Office of Assistant Secretary for Preparedness and Response - HHS |
April 24, 2020 |
December 01, 2020 |
$594,943 |
| THIS MODIFICATION 11 (ELEVEN) ACCOMPLISHES THE FOLLOWING:
1.) SUPPLEMENTAL FUNDING IN THE AMOUNT OF $12,736,273 PROVIDED FOR BASE PERIOD (CLIN 0001)
2.) PERIOD OF PERFORMANCE OF BASE PERIOD (CLIN 0001 - A AND B) IS EXTENDED FROM 6/30/2020 TO 6/30 |
CERUS CORPORATION |
Office of Assistant Secretary for Preparedness and Response - HHS |
June 17, 2016 |
December 31, 2021 |
$13,779,657 |
| EVIDATION COVID-19 DETECTION&FORECASTING MODEL PILOT |
EVIDATION HEALTH, INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
April 20, 2020 |
September 30, 2021 |
$720,000 |
| TANGEN SARS-COV-2 ASSAY |
TANGEN BIOSCIENCES, INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
April 15, 2020 |
October 31, 2020 |
$696,000 |
| A MULTI-SITE, RANDOMIZED, DOUBLE-BLIND, MULTI-ARM HISTORICAL CONTROL, COMPARATIVE TRIAL OF THE SAFETY AND EFFICACY OF HYDROXYCHLOROQUINE AND THE COMBINATION OF HYDROXYCHLOROQUINE AND FAMOTIDINE FOR THE TREATMENT OF MODERATE TO SEVERE COVID-19 DISEASE |
ALCHEM LABORATORIES CORP |
Office of Assistant Secretary for Preparedness and Response - HHS |
April 14, 2020 |
September 30, 2020 |
$20,747,018 |
| COVID-19 THE PURPOSE OF THIS MODIFICATION IS (1) EXTEND THE PERIOD OF PERFORMANCE FOR THE BASE PERIOD FROM MAY 31,2020 THROUGH SEPTEMBER 30, 2024, WITHOUT ADDITIONAL COSTS TO THE GOVERNMENT; (2) EXERCISE OPTIONS ONE (1) AND TWO (2); AND (3) REVISE TH |
MERCK SHARP & DOHME CORP. |
Office of Assistant Secretary for Preparedness and Response - HHS |
August 29, 2016 |
September 30, 2024 |
$38,033,570 |
| DIASORIN LIAISON SARS-COV-2 S1/S2 IGG |
DIASORIN INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
April 10, 2020 |
February 03, 2021 |
$180,045 |
| HEMEMICS HEMBOX: A RAPID, POINT-OF-CARE DIAGNOSTIC TOOL FOR NOVEL VIRUSES |
HEMEMICS BIOTECHNOLOGIES, INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
April 09, 2020 |
July 01, 2020 |
$638,000 |